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Introduction: There is inconsistent association between urate transporters SLC22A11 (organic anion transporter 4
(OAT4)) and SLC22A12 (urate transporter 1 (URAT1)) and risk of gout. New Zealand (NZ) Māori and Pacific Island
people have higher serum urate and more severe gout than European people. The aim of this study was to test
genetic variation across the SLC22A11/SLC22A12 locus for association with risk of gout in NZ sample sets.
Methods: A total of 12 single nucleotide polymorphism (SNP) variants in four haplotype blocks were genotyped
using TaqMan® and Sequenom MassArray in 1003 gout cases and 1156 controls. All cases had gout according to
the 1977 American Rheumatism Association criteria. Association analysis of single markers and haplotypes was
performed using PLINK and Stata.
Results: A haplotype block 1 SNP (rs17299124) (upstream of SLC22A11) was associated with gout in less admixed
Polynesian sample sets, but not European Caucasian (odds ratio; OR = 3.38, P = 6.1 × 10-4; OR = 0.91, P = 0.40,
respectively) sample sets. A protective block 1 haplotype caused the rs17299124 association (OR = 0.28, P = 6.0 × 10-4).
Within haplotype block 2 (SLC22A11) we could not replicate previous reports of association of rs2078267 with gout in
European Caucasian (OR = 0.98, P = 0.82) sample sets, however this SNP was associated with gout in Polynesian
(OR = 1.51, P = 0.022) sample sets. Within haplotype block 3 (including SLC22A12) analysis of haplotypes revealed a
haplotype with trans-ancestral protective effects (OR = 0.80, P = 0.004), and a second haplotype conferring protection
in less admixed Polynesian sample sets (OR = 0.63, P = 0.028) but risk in European Caucasian samples (OR = 1.33,
P = 0.039).
Conclusions: Our analysis provides evidence for multiple ancestral-specific effects across the SLC22A11/SLC22A12 locus
that presumably influence the activity of OAT4 and URAT1 and risk of gout. Further fine mapping of the association
signal is needed using trans-ancestral re-sequence data.* Correspondence: tony.merriman@otago.ac.nz
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Hyperuricemia is a primary risk factor for gout [1], leading
to the formation of monosodium urate crystals and gout in
some people. Genome-wide association studies (GWAS)
have identified 28 loci that account for approximately 6%
of the variance in serum urate (SU) levels in European
Caucasians [2]. Loci with the strongest effect encode pro-
teins involved in secretion and renal filtration of uric acid.
Two of these, SLC2A9 and ABCG2, have a very strong
effect in gout (risk allele odds ratio (OR) >2.0) in multiple
ancestral groups [2-5], whilst a third locus SLC17A1, has a
weaker effect (OR <1.5) [2,6,7]. The SLC22A11 (OAT4)
and SLC22A12 (URAT1) genes are also associated with SU
at a genome-wide level of significance [2]. However, evi-
dence for association with gout is ambiguous.
SLC22A11 (OAT4) and SLC22A12 (URAT1) encode
renal urate transporters located together on chromosome
11. SLC22A12 is expressed across multiple tissue types
and developmental stages, whilst SLC22A11 expression is
restricted to the kidneys and placenta [8]. URAT1 is a
high-affinity apical urate transporter [9], whilst OAT4
transports multiple organic anions and has low affinity for
urate [10]. Both URAT1 and OAT4 may play a role in
gout secondary to diuretic use due to competitive trans-
port of uric acid and diuretics [9,10].
Multiple single nucleotide polymorphisms (SNPs) at the
SLC22A11/SLC22A12 locus have been associated with SU
in European Caucasians, with two independent effects re-
ported within the locus [2]. These SNPs are spread across
a 1.3-Mb region and constitute four distinct linkage dis-
equilibrium (LD) blocks, two of which contain SLC22A11
and SLC22A12 [2]. This suggests a complex pattern of
association with SU in European Caucasians, at least. In
non-European populations, studies specifically on the
SLC22A12 gene have revealed associations with SU in
Chinese, Korean and Japanese sample sets that are con-
sistent with the those reported in European Caucasians
(rs505802 and SNPs in LD) [11-14] whilst additional asso-
ciations are evident in Chinese (rs475688 and rs7932775,
in low LD with rs505802) [14,15].
Variants in the haplotype block that includes SLC22A12
have previously been tested for association with gout
in European Caucasian with no association of rs505802
(OR = 0.99) [16] or rs478607 (OR = 0.97) [2]. There is con-
flicting evidence for association of common SLC22A12
variants with gout in Chinese sample sets [15,17]. Rare
variants in the SLC22A12 locus have been associated
with SU and gout in African-Americans [18] and gout
in Japanese [19] and Micronesians [20]. At SLC22A11,
Köttgen et al. [2] reported association of the minor (C) al-
lele of rs2078267 with prevalent gout in a meta-analysis of
European Caucasian cases nested within population-based
cohorts (OR = 1.16, P = 4.4 × 10-6). However, Stark et al.
[16] reported no evidence for association of rs17300741(OR = 1.02, P = 0.80; in very strong LD with rs2078267
(r2 = 0.96)) with gout. To our knowledge, no previous
studies have tested for association of SLC22A11 with SU
and gout in non-European populations.
There is ambiguity regarding association of SLC22A11
and SLC22A12 with gout - previous reports have studied
different population groups, with various methods for de-
termination of gout; clinical ascertainment using 1977
American Rheumatism Association (ARA) criteria [15,17],
self-report of physician-diagnosed gout, use of gout medi-
cations [2,18], a combination of self-report and exami-
nation of medical records [16]. Here our aim was to
clarify the association with gout according to the ARA
classification criteria at the SLC22A11-SLC22A12 locus in
multiple ancestral groups drawn from the New Zealand
(NZ) population, including Māori and Pacific Island.
These groups have a prevalence of gout double that of
European Caucasians [21], with earlier onset and more
severe gout and a higher prevalence of co-morbidities [6].Methods
Study participants
All gout cases (Additional file 1: Table S1; n = 1,003) had a
confirmed diagnosis of gout as defined by the 1977 ARA
preliminary classification criteria for acute gout [22] and
were recruited from community-based settings, primary
and secondary care. Controls (n = 1,156) self-reported
having no history of arthritis and were convenience-sam-
pled from workplaces and community focal points in the
Auckland region of NZ. Co-morbid conditions (type 2 dia-
betes, renal disease, hypertension, dyslipidemia and heart
disease) were self-reported. Ethical approval was given by
the NZ Multi-Region Ethics Committee and all partici-
pants provided written informed consent for the collec-
tion of samples and subsequent analysis.
Participants were divided into four sample sets ac-
cording to self-reported grandparental ancestry; NZ
European Caucasian (420 cases, 638 controls), Eastern
Polynesian (EP) - NZ Māori and Cook Island Māori
(315 cases, 349 controls), Western Polynesian (WP) -
Tongan, Samoan and Niuean (249 cases, 144 controls),
and a small mixed eastern and western ancestry group
(EP/WP) (19 cases, 25 controls) (Additional file 1:
Table S1). These groupings were based on previous
evidence for genetic heterogeneity between Eastern
and Western Polynesia (see [5] and references therein).
The EP sample set (predominantly NZ Māori) was fur-
ther split into two groups according to Polynesian
ancestry estimates obtained using 67 genomic control
markers [6]. Individuals of higher EP ancestry formed
the EP(High) sample set (256 cases, 187 controls) and
those of lower ancestry formed the EP(Low) sample set
(59 cases, 162 controls).
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Data on 1,000 genomes [23] for Caucasian (CEU) and
Han Chinese (CHB), as the most closely related and avail-
able population to the NZ Māori and Pacific populations,
was used to define haplotype blocks based on all the SNPs
previously associated with SU in GWAS studies within
the 1.3-Mb region of chromosome 11 (Additional file 2:
Figure S1). Four distinct haplotype blocks were identified
(block 1: approximately 26Kb upstream, Block 2: SLC2
2A11, Block 3: including SLC22A12, and block 4: approxi-
mately 840Kb downstream) (Additional file 1: Table S2)
and this information was then used to select variants for
genotyping (Additional file 2: Figure S2). SNPs were se-
lected largely on the basis of previous literature reports of
association with SU. For block 1 and block 4 both the
SNP most associated with SU (rs17299124; β = −3.75
μmolL-1, P = 8.6 × 10-16 and rs642803; β = −2.56 μmolL-1,
P = 4.5 × 10-14, respectively) and the most associated
tag-SNP (in high LD with all other associated SNPs
(rs475414; β = −2.38 μmolL-1, P = 3.1 × 10-12 and rs122
89836; β = −2.62 μmolL-1, P = 6.6 × 10-14, respectively)
were chosen [2,18,24]. For block 2 (SLC22A11) one tag-
SNP common to CEU and CHB was identified (rs693591)
and combined with the previously studied rs17300741 and
rs2078267 [2,24]. One tag-SNP for block 3 (SLC22A12)
was selected (rs476037) and included with the previously
reported SNPs rs3825018 (in complete LD with rs505802),
rs475688 and rs7932775 [2,24]. A fifth SNP (rs478607)
from block 3 was also added as representative of a second
(weaker) effect potentially independent of rs2078267
(SLC22A12) ([2]; β = −2.80 μmolL-1, P = 4.4 × 10-11)
(Additional file 2: Figure S3, S4). Three of the twelve chosen
SNPs have a predicted biological function according to
FuncPred [25]; rs3825018 is situated in a potential tran-
scription factor binding site and may enhance or silence
splicing, rs7932775 may also enhance or silence splicing
and rs476037 is situated at a potential miRNA binding site.
Genotyping
SNPs were genotyped using either TaqMan® assays (Applied
Biosystems, Foster City, CA, USA) in a Lightcycler® 480
Real-Time PCR System (Roche, Indianapolis, IN, USA)
(rs693591 (assay ID C_925815_10), rs17300741 (C_323
4214_10), rs3825018 (C_27162391_10)), rs475688 (C_9257
97_10), rs476037 (C_3108662_20), rs7932775 (C_3108
664_10), or the MassArray system (Sequenom iPLEXassay,
San Diego, CA, USA): rs17299124, rs642803, rs475414,
rs12289836, rs478607 and rs2078267.
Association analysis
Allelic ORs were obtained from a sex-adjusted logistic
regression in PLINK [26]. These were relevant to the
allele in-phase with the rs3825018 G allele as determined
using 1,000 genomes LD data. To assess experiment-wide significance a Bonferroni correction was applied to
P-values. A conservative correction factor of 48 was
applied to the single SNP analysis (P <0.00104; 12 SNPs
meta-analyzed by inverse-variance weighting over four
sample sets - EP(High), WP, EP/WP), all Polynesian (in-
cluding EP(Low)), European Caucasian and EP(Low),
and all five sample sets combined) and a factor of 12 for
the haplotype analysis (P <0.0042; meta-analysis of three
haplotype blocks over four sample sets). Interaction terms
for co-morbid phenotypes and ancestry were included in
the logistic regression model where appropriate.
Ancestrally defined sample sets were combined by
an inverse-variance weighted fixed-effect method, using
STATA 8.0 software [27]. A Q-statistic was calculated to
determine the heterogeneity between cohorts and for
SNPs showing heterogeneity (PHet <0.05) the fixed-effect
model was replaced with a random-effect model. Power
was calculated for a nominal P = 0.05 (Additional file 2:
Figure S5) [28]. All sample sets were adequately powered
(>80%) to detect moderate effects (OR = 1.5) at minor
allele frequency >0.1.
Haplotype association analysis
Haplotype imputation by expectation maximization was
performed in PLINK to produce most-likely haplotype
calls (haplotypes with a frequency <0.01 were excluded).
These data were then used to perform a sex-adjusted lo-
gistic regression in PLINK, producing ORs and P-values.
Inverse-variance weighted fixed-effect analysis in STATA
8.0 was performed to combine the independent datasets
(as described for the allelic association analysis).
Locus-specific gout genetic risk score
A weighted genetic risk score was calculated using the
most associated SNP in each of block one to three. The
gout risk score calculation was ((rs17299124(C) × β) +
(rs2078267(C) × β) + (rs3825018(G) × β)), where each
SNP ID followed by an allele in brackets denotes the
allele count per individual, and the β after each SNP
denotes the natural log of the ancestry-specific OR for
that allele. Individuals who did not have complete geno-
type information (9.22%) were excluded.
The mean genetic risk score was calculated for each
sample set and a two-tailed t-test performed to identify any
significant differences between case and control values. A
further sex-adjusted logistic regression was performed to
test association with gout. All risk-score analysis was con-
ducted in STATA 8.0.
Results
Allelic associations
The European Caucasian sample set revealed nominally
significant (P <0.05) associations with gout at two block-
3 SNPs: rs475688 and rs7932775 (SLC22A12; OR = 1.26,
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The EP(High) sample set revealed four nominally signifi-
cant associations within block 1 (rs17299124; OR = 2.77,
P = 0.019), block 2 (SLC22A11) (rs693591; OR = 1.41,
P = 0.031), and block 3 (SLC22A12) (rs3825018; OR= 1.46,
P = 0.028, and rs476037; OR= 1.56, P = 0.022). The EP
(Low) sample set showed no significant associations where-
as the WP sample set revealed association with the block-1
SNP rs17299124 (OR = 5.65, P = 0.011) and the block-3
SNP rs7932775 (OR = 1.49, P = 0.019). The mixed Eastern
and Western Polynesian sample set revealed a nominally
significant association at rs693591 (OR = 4.55, P = 0.025)
(Table 1).
Within block 1, observing that the effect of rs1729914
was stronger in the less admixed Polynesian sample sets
(EP(High), WP, EP/WP) (Table 1), we combined these
sample sets by inverse-variance weighting for rs17299124
and tested for association with gout in these sample
sets, revealing experiment-wide evidence for association
(Table 2; OR = 3.38, P = 6.1 × 10-4). The heterogeneity
P-value of 0.010 (in the combined analysis of all ances-
tries) suggested an ancestral specific effect. Based on this,
all SNPs were combined by inverse-variance weighting in
four groups - less admixed Polynesian (EP(High), WP,
EP/WP), all Polynesian (including EP(Low)), European
Caucasian and EP(Low), and the five sample sets com-
bined. Of the other SNPs, only block-3 rs3825018 ap-
proached experiment-wide significance in all ancestries
combined (OR = 1.27, P = 0.002). Because no nominal
association with block 4 was seen in any sample set the
relevant SNPs (rs12289836 and rs642803) were not in-
cluded in further analyses.
Block-1 to −3 SNPs rs17299124, rs2078267 and rs38
25018 were tested for association with SU levels in con-
trols (Additional file 1: Table S3). The only nominally
significant associations observed (P <0.05) were with
rs2078267 in less admixed Polynesian and total Polynesian
(β = 0.044 mmolL-1, P = 0.007 and β = 0.030 mmolL-1,
P = 0.022 respectively). The minor allele increased SU,
consistent with the increased risk mediated for gout by
the minor allele in these sample sets (Table 2). These asso-
ciations were, however, not significant after correcting
P-values for multiple testing (n = 12).
Interaction terms were included in the sex-adjusted
logistic regression analyses in order to test for interaction
between genotype (of the most associated SNP in blocks 1
to 3), gout and body mass index, type 2 diabetes, dyslipi-
demia, heart disease and hypertension in the European
Caucasian, less admixed Polynesian and total Polynesian
samples (Additional file 1: Table S4). There were no sig-
nificant interactions observed (after correcting for the
number of tests done, n = 45). We also tested for inter-
action with ancestry with significant interaction observed,
after correcting for the number of tests done (n = 3), withancestry for block-1 SNP rs17299124 (Pc = 9.9 × 10
-6) and
block-2 SNP rs2078267 (Pc = 2.6 × 10
-5). The interaction
with ancestry at rs17299124 was consistent with the
PHet = 0.01 in the inverse-variance weighted analysis with
the rs2078267 association also specific to Polynesian
(Table 2). The PInteraction at rs3825018 was 0.033.Haplotype association analysis
We initially combined by inverse-variance weighting hap-
lotypes in the same combinations of sample sets as used in
Tables 2 and 3. At block 1 there was a haplotype (rs475414
(allele T) - rs17299124 (allele A)) that exhibited significant
heterogeneity (PHet = 0.007) in the combined analysis of all
ancestries. Consistent with the rs17299124 data the effect,
which was protective, was restricted to the less admixed
Polynesian sample sets (OR = 0.28, P = 6.0 × 10-4). This
protective T-A haplotype was rarer in the less admixed
Polynesian sample set (Table 4 control frequency
0.044-0.052) compared with EP(Low) 0.203 and European
Caucasian 0.245.
At block 2 no haplotype association was observed. At
block 3 the only other experiment- wide significant asso-
ciation was observed, a protective haplotype in the com-
bined sample set (A-C-T-G-A; OR = 0.80, P = 0.004). This
haplotype was more common in European Caucasian
(control frequency of 0.717) than Polynesian (control fre-
quency range of 0.303-0.545). The block-3 G-T-C-G-G
haplotype showed evidence for heterogeneity (PHet =
0.014) in the combined analysis of all ancestries – closer
examination showed that this owed to a risk effect
in European Caucasian and more admixed Polynesian
(EP(Low)) (OR = 1.41, P = 0.007) and a protective effect in
less admixed Polynesian (OR = 0.63, P = 0.028) (Tables 3
and 4). The frequency of this haplotype varied conside-
rably, even within the Polynesian sample sets (Table 4
control frequency: WP 0.034, EP(High) 0.139, EP(Low)
0.131, European Caucasian 0.133).Gout genetic risk-score association
A weighted genetic risk score was calculated to deter-
mine the cumulative effect of the approximately 360-Kb
(block 1 to block 3) region on gout risk, using the most
associated marker in each ancestral block. Genetic
risk scores ranged from 0 to 18.03 with no European
Caucasian individual risk score being >7 (range 0 to
6.21). In each sample set the average case risk-score was
significantly larger than the average control risk-score
(Table 5). There was a significant association between
gout and the genetic risk score in EP(High) (OR = 1.22,
P = 0.002) and WP (OR = 1.14, P = 0.041) but not in
European Caucasian (OR = 1.01, P = 0.80), EP(Low)
(OR = 1.03, P = 0.77) or the small EP/WP sample set
(OR = 1.32, P = 0.21).
Table 1 Allelic association analysis of the twelve chromosome 11 SNPs with gout





Pe Allele Freq. ORe
(95% CI)
Pe Allele Freq. ORe
(95% CI)
Pe Allele Freq. ORe
(95% CI)
Pe Allele Freq. ORe
(95% CI)
Pe
Case Con Case Con Case Con Case Con Case Con
1a T/C 0.571 0.531 1.19 0.257 0.566 0.601 1.01 0.957 0.403 0.409 1.06 0.758 0.500 0.400 1.65 0.412 0.566 0.564 1.02 0.868
(0.88,1.61) (0.63,1.64) (0.75,1.49) (0.50,5.48) (0.84,1.24)
1 rs17299124 11:64256859 C/A 0.976 0.950 2.77 0.019 0.821 0.801 1.20 0.577 0.994 0.957 5.65 0.011 0.974 0.947 3.00 0.461 0.733 0.752 0.91 0.401
(1.18,6.50) (0.63,2.32) (1.49,21.39) (0.16,55.71) (0.73,1.14)
2 rs693591 11:64325069 C/G 0.522 0.449 1.41 0.031 0.315 0.291 1.13 0.630 0.373 0.367 1.00 0.992 0.526 0.260 4.55 0.025 0.139 0.135 0.95 0.733
(1.03,1.92) (0.68,1.89) (0.72,1.40) (1.21,17.06) (0.72-1.26)
2 rs17300741 11:64331462 A/G 0.819 0.789 1.30 0.187 0.604 0.557 1.29 0.312 0.808 0.830 0.76 0.213 0.806 0.750 1.42 0.595 0.476 0.439 1.05 0.611
(0.88,1.91) (0.78,2.14) (0.49,1.17) (0.39,5.24) (0.87,1.27)
2 rs2078267 11:64334114 C/T 0.938 0.910 1.78 0.063 0.651 0.606 1.19 0.526 0.980 0.944 2.20 0.071 0.921 0.886 1.21 0.815 0.479 0.456 0.98 0.816
(0.97,3.26) (0.70,2.00) (0.94,5.17) (0.24,6.11) ([0.81,1.18]
3 rs3825018 11:64358809 G/A 0.739 0.674 1.46 0.028 0.500 0.447 1.37 0.206 0.726 0.712 1.16 0.404 0.842 0.660 1.83 0.316 0.305 0.267 1.22 0.065
(1.04,2.06)] (0.84,2.23) (0.82,1.66) (0.56,5.98) (0.99,1.50)
3 rs475688 11:64364291 T/C 0.433 0.427 1.10 0.543 0.370 0.295 1.66 0.073 0.409 0.461 0.78 0.145 0.556 0.420 1.72 0.391 0.269 0.236 1.26 0.043
(0.80,1.52) (0.95,2.89) (0.56,1.09) (0.50,5.97) ([1.01,1.57)
3 rs7932775 11:64367862 C/T 0.496 0.478 1.03 0.866 0.373 0.320 1.36 0.278 0.489 0.415 1.49 0.019 0.500 0.396 1.00 1.000 0.213 0.174 1.32 0.033
(0.76,1.40) (0.78,2.35) (1.07,2.09) (0.35,2.90) (1.02,1.69)
3 rs476037 11:64369540 A/G 0.254 0.206 1.56 0.022 0.149 0.136 1.10 0.787 0.250 0.303 0.78 0.165 0.368 0.250 2.58 0.161 0.088 0.089 1.03 0.846
(1.07,2.28) (0.56,2.16) (0.55,1.11) (0.69,9.68) (0.74,1.43)
3 rs478607 11:64478063 G/A 0.241 0.268 0.85 0.359 0.279 0.184 1.72 0.080 0.196 0.166 1.48 0.085 0.211 0.225 0.82 0.766 0.167 0.144 1.27 0.077
(0.60,1.20) (0.94,3.15) (0.95,2.31) (0.23,2.98) (0.98,1.66)
4 rs12289836 11:65436888 A/G 0.621 0.622 0.94 0.711 0.660 0.631 1.07 0.810 0.693 0.746 0.80 0.237 0.790 0.725 1.22 0.766 0.645 0.683 0.85 0.109
(0.68,1.30] (0.62,1.85) (0.55,1.16)] (0.34,4.40) (0.69,1.04)
4 rs642803 11:65560620 T/C 0.454 0.458 1.00 0.975 0.500 0.474 1.26 0.364 0.413 0.421 0.92 0.624 0.500 0.368 0.71 0.620 0.448 0.474 0.93 0.467
(0.73,1.36] (0.77,2.07) (0.66,1.29) (0.18,2.75) (0.77,1.13)
aLD block as shown in Additional file 2: Figure S1 and S2, block 1: upstream, block 2: SLC22A11, block 3: SLC22A12, block 4: downstream. brs2078267, rs3825018 and rs476037 showed some evidence for a departure
from Hardy-Weinberg equilibrium in the WP controls (P = 0.007, 0.001 and 0.006, respectively), rs2078267 in the EP/WP cases (P = 0.005) and rs476037 in the European Caucasian cases (P = 0.023). None were significant
after correction for multiple testing (P <0.00042 (correction factor of 120; 10 datasets × 12 SNPs)). cBase position is according to Genome Reference Consortium human genome build 37 (GRCh37). dEffect/Other, alleles;
all odds ratios (ORs) are calculated relevant to the effect allele defined as the allele in-phase with rs3825018 G allele according to 1,000 Genomes linkage-disequilibrium data. eOR, allelic OR (adjusted for sex); P, allelic
asymptotic P-value. Genotyping success rate: rs475414: 97.55%; rs17299124: 94.35%; rs693591: 98.75%; rs17300741: 97.59%; rs2078267: 95.41%; rs3825018: 99.40%; rs475688: 98.75%; rs7932775: 92.40%; rs476037:




























Ph(95% CI) (95% CI) (95% CI) (95% CI)
1a rs475414 11:64241844 T/C 1.02 0.862 0.990 1.15 0.233 0.727 1.12 0.270 0.839 1.07 0.376 0.861
(0.85,1.22) (0.92,1.43) (0.92,1.34) (0.93,1.23)
1 rs17299124 11:64256859 C/A 0.94 0.539 0.425 3.38 6.1 × 10,4 0.674 1.95 0.006 0.153 1.71 0.109 0.010
(0.76,1.16) (1.69,6.79) (1.21,3.15) (0.89,3.28)
2 rs693591 11:64325069 C/G 0.99 0.942 0.559 1.25 0.051 0.053 1.23 0.047 0.113 1.12 0.167 0.087
(0.78,1.26) (1.00,1.57) (1.00,1.51) (0.95,1.33)
2 rs17300741 11:64331462 A/G 1.08 0.402 0.446 1.04 0.793 0.173 1.10 0.469 0.254 1.07 0.396 0.388
(0.90,1.29) (0.78,1.38) (0.86,1.40) (0.92,1.24)
2 rs2078267 11:64334114 C/T 1.00 0.999 0.499 1.84 0.012 0.804 1.51 0.022 0.591 1.08 0.370 0.169
(0.84,1.20) (1.14,2.95) (1.06,2.14) (0.91,1.28)
3 rs3825018 11:64358809 G/A 1.24 0.028 0.660 1.33 0.020 0.568 1.34 0.008 0.767 1.27 0.002 0.822
(1.02,1.50) (1.05,1.69) (1.08,1.66) (1.10,1.48)
3 rs475688 11:64364291 T/C 1.31 0.011 0.360 0.95 0.683 0.216 1.03 0.768 0.096 1.13 0.109 0.093
(1.06,1.60) (0.76,1.20) (0.84,1.27) (0.97,1.32)
3 rs7932775 11:64367862 C/T 1.32 0.017 0.923 1.21 0.095 0.256 1.23 0.051 0.412 1.26 0.004 0.550
(1.05,1.66) (0.97,1.51) (1.00,1.51) (1.08,1.48)
3 rs476037 11:64369540 A/G 1.05 0.770 0.874 1.25 0.480 0.014 1.19 0.461 0.036 1.08 0.423 0.070
(0.78,1.40] (0.67,2.34) (0.75,1.89) (0.89,1.31)
3 rs478607 11:64478063 G/A 1.33 0.020 0.371 1.04 0.785 0.148 1.13 0.337 0.109 1.19 0.056 0.167
(1.05,1.70) (0.79,1.36) (0.88,1.44) (1.00,1.43)
4 rs12289836 11:65436888 A/G 0.87 0.156 0.435 0.89 0.327 0.717 0.91 0.423 0.791 0.88 0.085 0.863
(0.72,1.05) (0.70,1.13) (0.73,1.14) (0.76,1.02)
4 rs642803 11:65560620 T/C 0.97 0.728 0.267 0.95 0.662 0.862 1.00 0.982 0.726 0.96 0.586 0.818
(0.81,1.16) (0.76,1.19) (0.81,1.23) (0.84,1.11)
aLD block as shown in Additional file 2: Figure S1 and S2, block 1: upstream, block 2: SLC22A11, block 3: SLC22A12, block 4: downstream. bBase position is
according to Genome Reference Consortium human genome build 37 (GRCh37). cEffect/Other, effect allele and other allele, all odds ratios (ORs) are calculated
relevant to the effect allele defined as the allele in-phase with rs3825018 G allele according to 1,000 genomes linkage disequilibrium data. dCombining EP(L) and
NZ European Caucasian sample sets. eCombining the EP(H), WP and EP/WP sample sets. fCombining the Eastern Polynesian EP high (EP(H)), EP low (EP(L)), Western
Polynesian (WP) and EP/WP sample sets. gCombining the EP(H), EP(L), WP, EP/WP and NZ European Caucasian sample sets. hOR: inverse-variance weighted analysis
OR (adjusted for sex); P: inverse-variance weighted analysis P-value; Het P: heterogeneity P-value, inverse-variance weighted analyses were reanalyzed using a
random-effects model if the Het P was <0.05.
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We analyzed three haplotype blocks - a region upstream
of SLC22A11 containing no known genes (block 1),
SLC22A11 (block 2) and SLC22A12 (block 3). Collectively
our data indicate a complex pattern of association that is
ancestry-dependent, with risk appearing to be driven by
protective haplotypes that are at a higher frequency in
European Caucasian than in people of Polynesian ances-
try. The genetic risk-score analysis (Table 5) emphasized
the relative important of the locus on the risk of gout in
less admixed Polynesian (% variance explained 1.4 to 1.9)
compared to the more admixed Polynesian and European
Caucasian sample sets (<0.1% variance explained). Com-
mon variation in this locus is likely to be part of theexplanation for why Polynesian people exhibit higher SU
and a higher prevalence of gout [6,21].
The block-1 region has previously never been studied
for association with gout. The single SNP data of
rs17299124 showed the strongest effect in the less
admixed Polynesian sample sets (OR = 3.38) with non-
significant effects closer to OR = 1.00 in the more
admixed Eastern Polynesian and European Caucasian
sample sets (OR = 1.20 and 0.91, respectively). This SNP
is therefore a novel candidate risk variant to test for
association with gout in South East Asian populations
(ancestrally related to Polynesian). Haplotype analysis
indicated that this effect in less admixed Polynesians is
driven by a genetic variant that protects from gout. The
Table 3 Inverse-variance weighted analysis of block- 1 to -3 haplotypes
European Caucasian and low ancestry Polynesianb High ancestry Polynesianc Polynesiand All ancestriese





Pf(95% CI) (95% CI) (95% CI) (95% CI)
Block 1 (rs475414|rs17299124)
C|C 0.94 0.501 0.795 0.89 0.305 0.884 0.91 0.349 0.936 0.92 0.242 0.978
(0.78,1.13) (0.71,1.11) (0.74,1.11) (0.80,1.06)
T|A 1.07 0.549 0.379 0.28 6.0 × 10,4 0.512 0.50 0.006 0.120 0.56 0.103 0.007
(0.86,1.32) (0.14,0.58) (0.31,0.82) (0.28,1.12)
T|C 1.02 0.848 0.584 1.30 0.022 0.914 1.29 0.019 0.965 1.14 0.093 0.572
(0.83,1.25) (1.04,1.63) (1.04,1.56) (0.98,1.33)
Block 2 (rs693591|rs17300741|rs2078267)
C|A|C 0.97 0.800 0.726 1.24 0.070 0.128 1.20 0.083 0.219 1.10 0.253 0.179
(0.76,1.24) (0.98,1.56) (0.98,1.49) (0.93,1.30)
G|A|C 1.08 0.468 0.842 0.78 0.037 0.446 0.83 0.083 0.368 0.94 0.440 0.204
(0.88,1.31) (0.61,0.99) (0.67,1.03) (0.81,1.10)
G|G|C , , , 1.35 0.093 0.369 1.31 0.113 0.509 , , ,
(0.95,1.91) (0.94,1.83)
G|G|T 0.97 0.706 0.682 0.57 0.022 0.797 0.69 0.042 0.600 0.91 0.252 0.316
(0.81,1.15) (0.35,0.92) (0.49,0.99) (0.77,1.07)
Block 3 (rs3825018|rs475688|rs7932775|rs476037|rs478607)
A|C|T|G|A 0.82 0.040 0.953 0.76 0.035 0.272 0.77 0.024 0.451 0.80 0.004 0.594
(0.67,0.99) (0.59,0.98) (0.62,0.97) (0.68,0.93)
G|C|C|G|A 1.06 0.816 0.425 1.31g 0.105 0.969 1.23g 0.183 0.543 1.22h 0.142 0.746
(0.66,1.69) (0.95,1.81) (0.91,1.67) (0.94,1.60)
G|C|C|G|G , , , 1.33 0.116 0.702 1.29 0.151 0.752 , , ,
(0.93,1.90) (0.91,1.81)
G|T|C|G|A , , , 0.93 0.730 0.905 , , , , , ,
(0.63,1.39)
G|T|C|G|G 1.41 0.007 0.248 0.63 0.028 0.821 0.86 0.690 0.028 1.01 0.984 0.014
(1.10,1.82) (0.41,0.95) (0.41,1.80) (0.61,1.66)
G|T|T|A|A 1.01 0.947 0.731 1.19 0.573 0.029 1.07 0.590 0.062 1.06 0.579 0.118
(0.87,1.29)(0.75,1.36) (0.66,2.14) (0.84,1.36)
aBlock 1 (rs475414|rs17299124), block 2 (rs693591|rs17300741|rs2078267), block 3. (rs3825018|rs475688|rs7932775|rs476037|rs478607) excluding frequency <0.01.
bCombining the Eastern Polynesian (EP) low (EP(L)) and NZ European Caucasian sample sets. cCombining the EP high (EP(H)), Western Polynesian (WP) and EP/WP
sample sets. dCombining the EP(H), EP(L), WP, and EP/WP sample sets. eCombining the EP(H), EP(L), WP, EP/WP and NZ European Caucasian sample sets. fOR:
Inverse-variance weighted analysis odds ratio (adjusted for sex); P: inverse-variance weighted analysis P-value; Het P: heterogeneity P-value, inverse-variance
weighted analyses were reanalyzed using a random-effects model if the Het P was <0.05. gEP/WP cohort was excluded from this meta-analysis owing to no female
controls having the G|C|C|G|A haplotype.
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70, January 2013) suggests that the effect seen at
rs17299124 may operate by influencing the expression of a
nearby gene, perhaps SLC22A11. Previously rs2186571 has
been associated with SU levels in the Pacific Micronesian
population of Kosrae [20]. This SNP, which maps several
hundred kilobases upstream of SLC22A11, further impli-
cates this region in the etiology of gout. There are two in-
versions and a deletion spanning this region [29], possiblyable to cause a difference in the regulation of SLC22A11
or SLC22A12 expression.
At block 2 (SLC22A11) rs2078267 has previously been
convincingly associated with gout in European Caucasian
(OR = 0.88, P = 2.3 × 10-5; [2]) but the NZ European
Caucasian sample set is inconsistent with these findings
(OR = 0.98, P = 0.82). While low power may be a factor,
we expected to observe an effect size consistent with that
reported by Köttgen et al. [2] (OR = 1.14 to the C allele).
Table 4 Sample set-specific haplotype association analysis at haplotype blocks 1 to 3












Case Con Case Con Case Con Case Con Case Con
Block 1 (rs475414|rs17299124)
C|C 0.437 0.472 0.86 0.321 0.434 0.397 1.00 0.988 0.598 0.595 0.94 0.745 0.500 0.579 0.75 0.648 0.430 0.450 0.93 0.471
(0.63,1.16) (0.61,1.62) (0.67,1.34) (0.22,2.60) (0.76,1.14)
T|A 0.024 0.051 0.35 0.017 0.179 0.203 0.81 0.525 0.004 0.044 0.12 0.009 0.026 0.053 0.33 0.461 0.262 0.245 1.10 0.393
(0.15,0.83) (0.42,1.56) (0.03,0.59) (0.02,6.19) (0.88,1.38)
1.34 0.063 0.387 0.400 1.18 0.562 0.396 0.361 1.24 0.228 0.474 0.368 1.53 0.486 0.302 0.301 1.00 0.984
T|C 0.539 0.477 (0.98,1.82) (0.67,2.09) (0.88,1.76) (0.46,5.08) (0.80,1.24)
Block 2 (rs693591|rs17300741|rs2078267)
C|A|C 0.525 0.458 1.38 0.047 0.315 0.298 1.05 0.849 0.373 0.371 1.02 0.933 0.528 0.283 3.49 0.063 0.139 0.134 0.95 0.698
(1.00,1.90) (0.63,1.77) (0.72,1.43) (0.93,13.01) (0.72,1.25)
G|A|C 0.299 0.350 0.77 0.136 0.287 0.272 1.13 0.654 0.436 0.461 0.83 0.288 0.278 0.478 0.38 0.106 0.329 0.302 1.07 0.543
(0.54,1.09) (0.66,1.95) (0.60,1.17) (0.12,1.23) (0.87,1.32)
G|G|C 0.11 0.102 1.09 0.734 0.046 0.040 0.94 0.914 0.17 0.121 1.72 0.032 0.111 0.13 0.76 0.758 , , , ,
(0.66,1.83) (0.28,3.14) (1.05,2.83) (0.14,4.30)
G|G|T 0.061 0.090 0.56 0.070 0.352 0.381 0.87 0.607 0.019 0.043 0.50 0.117 0.083 0.109 0.93 0.932 0.525 0.556 0.98 0.830
(0.30,1.05) (0.52,1.47) (0.21,1.19) (0.19,4.68) (0.81,1.18)
Block 3 (rs3825018|rs475688|rs7932775|rs476037|rs478607)
A|C|T|G|A 0.273 0.327 0.71 0.053 0.510 0.545 0.81 0.420 0.290 0.303 0.89 0.520 0.167 0.421 0.29 0.088 0.678 0.717 0.82 0.059
(0.50,1.01) (0.48,1.36) (0.61,1.28) (0.07,1.21) (0.67,1.01)
G|C|C|G|A 0.179 0.136 1.26 0.283 0.078 0.115 0.78 0.582 0.159 0.129 1.37 0.214 0.139 0.053 , 0.997 0.035 0.024 1.19 0.534
(0.83,1.93) (0.32,1.88) (0.83,2.26) (0.68,2.08)
G|C|C|G|G 0.116 0.108 1.14 0.599 0.039 0.038 0.82 0.767 0.142 0.114 1.54 0.100 0.111 0.105 1.71 0.659 , , , ,
(0.69,1.89) (0.23,2.98) (0.92,2.59) (0.16,18.73)
G|T|C|G|A 0.057 0.068 0.84 0.574 0.000 0.016 , 0.998 0.111 0.102 1.01 0.971 0.139 0.053 0.96 0.968 , , , ,
(0.46,1.55) (0.59,1.73) (0.14,6.67)
G|T|C|G|G 0.098 0.139 0.64 0.068 0.226 0.131 2.03 0.036 0.026 0.034 0.63 0.354 0.056 0.105 0.31 0.301 0.161 0.133 1.33 0.039
(0.40,1.03) (1.05,3.95) (0.24,1.68) (0.04,2.83) (1.01,1.75)
G|T|T|A|A 0.266 0.213 1.53 0.030 0.128 0.131 0.90 0.776 0.264 0.314 0.78 0.183 0.361 0.263 2.28 0.300 0.088 0.087 1.04 0.836
(1.04,2.24) (0.44,1.85) (0.55,1.12) (0.48,10.80) (0.74,1.44)
aHap, haplotypes listed in alphabetical order; those with a frequency <0.01 were excluded. bEast Polynesian (High), individuals with a STRUCTURE ancestry level ≥0.67. cEast Polynesian (Low), individuals with a















Table 5 Genetic risk score analysis
Mean ± standard deviation ū1-ū2a ta Pa ORb Pb Variance
explained (%)cCase Control (95% CI)a (95% CI)
East Polynesian (H) 10.93 ± 1.56 10.45 ± 1.91 0.48 2.71 0.007 1.22 0.002 1.38
(0.13, 0.83) (1.07-1.39)
East Polynesian (L) 4.81 ± 1.70 4.68 ± 1.96 0.13 0.47 0.64 1.03 0.77 0.09
(-0.44, 0.71) (0.84-1.26)
West Polynesian 17.24 ± 1.21 16.57 ± 2.95 0.67 2.43 0.016 1.14 0.041 1.89
(0.13, 1.22) (1.01-1.30)
Polynesian 11.16 ± 1.54 10.23 ± 2.04 0.93 1.54 0.14 1.32 0.21 5.11
(-0.31, 2.18) (0.85-2.05)
European Caucasian 3.02 ± 1.60 2.94 ± 1.52 0.08 0.75 0.45 1.01 0.80 0.04
(-0.13, 0.28) (0.93-1.11)
aū1-ū2, difference in means (case (ū1) minus control (ū2)); t, t-value, P, two-tailed t-test P-value. bOR, odds ratio (adjusted by sex); P, logistic regression P-value.
cBased on pseudo-R2 calculated during logistic regression.
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cases are important at SLC22A11. In the Köttgen et al.
study the association was restricted to the prevalent gout
cases (OR = 0.86, P = 4.4 × 10-6) and not observed in the
incident cases (OR = 0.96, P = 0.55). Ascertainment in the
prevalent group was dominated by a combination of self-
report or use of urate-lowering medication and colchicine
(prescribed for alleviating pain from acute gout), whereas
the incident group was ascertained, as were the NZ gout
cases (OR = 0.98, P = 0.82), by use of the ARA classifi-
cation criteria for gout, a superior ascertainment method
[30] (although the NZ cases were ascertained by clinical
examination whereas the incident ones by a self-adminis-
tered questionnaire [31]). It is therefore counter-intuitive
that the association of SLC22A11 should be restricted to
gout cases ascertained by less stringent criteria. Under-
standing this intriguing paradox may reveal new informa-
tion on the role of SLC22A11 (OAT4) in the control of SU
and in the risk of gout. There are physiological data sho-
wing that OAT4 mediates hydrochlorothiazide-induced
hyperuricemia [10] and also evidence for interaction of
rs2078267 with diuretic use in determining the risk of
gout [32]. It is possible that non-additive interaction with
diuretics could be a factor in the inconsistencies. In the
Polynesian analysis there was nominal evidence for asso-
ciation with gout at rs2078267, with the minor allele
conferring risk (OR = 1.51, P = 0.022), consistent with
the urate-increasing effect of this allele in European
Caucasians [2]. However this association was not signifi-
cant when corrected for multiple testing. Given the lower
allele frequency of this variant in Polynesians (<0.10 in the
less admixed samples), a larger sample size is required for
more robust conclusions about the possible role of
SLC22A11 in gout in Polynesian people.
At SLC22A12 the clearest findings came from analysis
of haplotype association. There was a gout-protectivevariant associated in the combined analysis (A-C-T-G-A;
OR = 0.80, P = 0.004), with a consistent direction of effect
in Polynesians and European Caucasians. There was also a
haplotype with ancestral specific effects; G-T-C-G-G was
protective in the less admixed Polynesian sample sets, yet
conferred risk in the more admixed EP and European
Caucasian sample sets. Our data therefore suggest that
multiple common variants within the SLC22A12 locus
contribute to the risk of gout, in a population-dependent
manner. In the European Caucasian sample set there were
nominal P-values for rs475688 and rs7932775 of 0.043
(OR = 1.26) and 0.033 (OR = 1.32), respectively. This is, to
our knowledge, the first report of nominally significant as-
sociation of SLC22A12 with gout in European Caucasians.
However, given the likely weak effect, confirmation of this
will require larger gout sample sets.
The block-3 SNP rs475688, in moderate LD (r2 = 0.80)
with rs3825018 in European Caucasians but low LD in
CHB and Polynesians (r2 = 0.33 and 0.36, respectively)
(Additional file 2: Figures S2 and S3), showed weak
evidence for association with gout in the NZ European
Caucasian sample set (OR = 1.26, P = 0.04) consistent with
the minor (T) allele increasing SU levels in Caucasians
(β = 3.28 μmolL-1, P = 1.3 × 10-17) [2]. This variant,
however, has been associated with gout and SU in Han
Chinese and Solomon Island (Melanesian) sample sets with
the T allele conferring protection against gout (OR = 0.54,
P = 1 × 10-4) and decreasing serum urate levels (β = −11.90
μmolL-1, P = 0.02) [15], a direction of association opposite
to that observed in NZ European Caucasians. This oppos-
ite effect between Polynesians and European Caucasians
at rs475688 is consistent with the opposing direction of
association seen with the block-3 G-T-C-G-G haplotype
(rs475688 is the second marker) between less admixed
Polynesians, and European Caucasians and the more ad-
mixed Eastern Polynesians. It will be informative to test
Flynn et al. Arthritis Research & Therapy 2013, 15:R220 Page 10 of 11
http://arthritis-research.com/content/15/6/R220this haplotype for association with SU and gout in Asian
and other Pacific populations.
Conclusions
We present several important findings: 1) novel asso-
ciation of rs17299124 upstream of SLC22A11 with gout in
Polynesians and not Caucasians, which is driven by a pro-
tective effect; 2) evidence for association of the SLC22A11
SNP rs2078267 with gout in Polynesians with the pre-
viously reported association in European Caucasians not
replicated; and 3) the SLC22A12 analysis was the first
report of nominally significant association with gout in
European Caucasians, with the haplotype analysis sugges-
ting multiple alleles conferring risk at SLC22A12 in an
ancestry-specific manner.Additional files
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